sugar formulated recombinant FVIII

05/01/2001 - "These results show that rFVIII-FS is a safe and effective for long-term treatment of patients with haemophilia A."
01/01/2015 - "This study demonstrates the effectiveness of CI with rFVIII-FS during surgery in patients with severe haemophilia A in a clinical practice setting."
01/01/2015 - "Patients with severe haemophilia A who received rFVIII-FS by CI during and after surgery were included in this study if they had more than 150 exposure days (EDs) to any FVIII product and had no history of inhibitors before CI. "
11/01/2012 - "The effect of once-a-week prophylaxis with BAY 79-4980 (35 IU/kg) compared with three times-per-week rFVIII-FS (25 IU/kg) in previously treated, severe haemophilia A patients was evaluated in a 52-week, double-blind, two-arm, randomised, controlled study. "
05/01/2009 - "We tested the stability of rFVIII-FS under CI conditions and conducted a single-centre, open-label, phase III study to evaluate the efficacy and safety of CI using rFVIII-FS in haemophilia A patients undergoing surgery. "

06/01/2013 - "Routine prophylaxis with rFVIII-FS leads to a significant reduction in bleeding as compared with on-demand treatment. "
11/01/2012 - "Previous clinical studies showed extended protection from bleeding after a single injection of BAY 79-4980 (13.3 ± 6.2 days) compared with rFVIII-FS (7.2 ± 1.7 days). "
05/01/2014 - "Following randomization to prophylaxis with rFVIII-FS, bleeding frequency was effectively reduced. "
01/01/2014 - "Annualized bleeding rate in patients treated with 3× per week rFVIII-FS significantly correlated with VWF:Ag and age (P = 0.038 and 0.021 respectively). "
01/01/2008 - "Of these bleeding episodes, 85.4% were successfully treated with one or two infusions of rFVIII-FS. "

01/01/2010 - "Secondary prophylaxis with rFVIII-FS significantly reduced the frequency of hemarthroses compared with on-demand therapy in adult patients with severe hemophilia A."

01/01/2008 - "Patients accumulated a mean (+/- SD) of 187 (121) EDs to rFVIII-FS and received a total of 39,627 infusions, mainly for prophylaxis and for the treatment of 4,283 spontaneous or trauma-related bleeds during an average observation time of 710 (136) days. "

09/01/2008 - "The prophylactic infusions used a fixed dose of 35 IU/kg rFVIII-FS, but varied in the amount of pegylated liposomes used for reconstitution (4.2, 12.6, or 22.1 mg/kg of body weight or water as a control). "